Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Breakthrough Research by Myko San Discovers How Mushroom Extracts Fight Cancer in Culture
  • USA - English


News provided by

Dr Myko San-Health from Mushrooms

Nov 21, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Zagreb, Croatia (PRWEB) November 21, 2013 -- A team of Croatian scientists led by Professors Drazenka Komes and Ksenija Durgo from the Faculty of Food Technology and Biotechnology of the University of Zagreb, and Dr. Ivan Jakopovich from Dr Myko San – Health from Mushrooms have published an important work in the newest issue of International Journal of Medicinal Mushrooms (Begell House, New York). They have tested medicinal mushroom products on 4 types of human cancers (bowel carcinoma, lung adenocarcinoma, small-cell lung cancer, and brain astrocytoma) and found that they can destroy tumor cells by damaging their membranes and mitochondria, the tumor cells’ ‘power plants’.

Medicinal mushrooms have been used in traditional medicine for thousands of years. Scientific research tested medicinal mushrooms for 60 years. More than 50.000 published scientific papers and 400 clinical trials have conclusively proven that they halt or slow down cancer growth. Several official medical drugs against cancer (isolated compounds PSK/Krestin, Lentinan, Schizophyllan in Japan, and PSP in China) and thousands of dietary supplements from medicinal mushrooms are the results of this research.

The Croatian team was trying to explain the impact of polysaccharides and polyphenol content of medicinal mushrooms on the cytotoxic effects (toxicity to cancer cells), and the mechanisms behind their ability to kill cancer cells. As part of the experiment, the researchers have used both simple extracts from one mushroom species or isolated active compounds (PSP, ImmunoBran MGN-3, and Beta glucan), and complex extract combinations of multiple mushroom species (6 products from Dr Myko San–Health from Mushrooms company, based on the research the company has done with Rudjer Boskovic Institute). Exactly this detail enabled them to solve the problem that has been baffling the scientists for an entire decade.

The scientific community was split into two camps on the issue of extract combinations and their interactions. One side expected the blends to reduce the overall cytotoxic effect by diluting the active compounds and introducing negative interactions. The other maintained that the blends would be more effective, as they would simultaneously influence more processes inside the cancer cells. The preceding research efforts gave mixed results.

This research has conclusively proven that quality medicinal mushroom extract combinations possess much stronger antitumor ability than isolated active compounds. The blends were more effective on all tumor types and stopped the growth of cancer cells, in some cases, better than 100-fold doses of simple preparations. It became obvious why the previous research was ambiguous: the efficacy of medicinal mushroom preparation against cancer is not only determined by the dose of the active ingredient(s), but also by the quality of all components of the blend. Therefore, it’s possible to obtain weaker or stronger results using the blends - and it entirely depends on the quality of the blend.

One of the authors, Dr. Ivan Jakopovich, founder of Dr Myko San-Health from Mushroom company, the first producer of medicinal mushroom preparations in Europe explains:

“Medicinal mushroom extracts exhibit strong antitumor effects and can be very helpful, especially combined with standard cancer therapy. They are ‘chronically’ underused in Western medicine.

Extract blends are superior because they induce synergistic enhancement of active compounds. This leads to reduced tumor cell division and earlier cell death, but also activates more immunological mechanisms in the body.

Medicinal mushrooms work differently than most medical drugs. Their extracts are very effective against cancer, but if we try to increase active compound concentrations and purify them, they start to lose effectiveness. This is probably caused by a great number of still undiscovered active compounds working in synergy, but also by the inertness of inactive ingredients, which do not impair the function of the active ones.

The fortunate thing about medicinal mushrooms is that this huge mix of compounds does not cause negative interactions, so we can get very strong products if we extract them just right. It doesn't matter that they are not pharmaceutically 100% pure.”

About Myko San
Myko San is the 1st producer of medicinal mushroom supplements in Europe (since 1990), and a respected leader (the only European company host of the International Medicinal Mushroom Conference, in 2011). Its founder Dr. Ivan Jakopovich is a member of the International Society for Mushroom Science, the New York Academy of Sciences and a member of the editorial board of the most highly ranked medicinal mushroom journal the 'International Journal for Medicinal Mushrooms'. Myko San company and Dr. Jakopovich are known worldwide as one of the most important promoters of the wider use of health benefit potential of medicinal mushrooms and contributors in medicinal mushroom research.

tags: cancer, medicinal mushrooms, extracts, Myko San, research

Neven Jakopovic, Dr Myko San-Health from Mushrooms, http://www.mykosan.com, +385 915810715, [email protected]

Modal title

Dr. Ivan Jakopovich, founder and general manager of Myko San, is a top expert and a recognized authority for medicinal mushrooms and their use.
Dr. Ivan Jakopovich, founder and general manager of Myko San, is a top expert and a recognized authority for medicinal mushrooms and their use.
Famous medicinal mushroom Lentinus edodes (Shiitake). Used traditionally (and verified scientifically) for cancer, to lower cholesterol and blood sugar, and to boost the immune system against viruses.
Famous medicinal mushroom Lentinus edodes (Shiitake). Used traditionally (and verified scientifically) for cancer, to lower cholesterol and blood sugar, and to boost the immune system against viruses.
Myko San supplement Agarikon.1 kills cancer cells in culture. Left is the control, on the right a 50% concentration of a single component; the cytotoxic effect on squamous cell cancer is very strong.
Myko San supplement Agarikon.1 kills cancer cells in culture. Left is the control, on the right a 50% concentration of a single component; the cytotoxic effect on squamous cell cancer is very strong.
Dr. Ivan Jakopovich, founder and general manager of Myko San, is a top expert and a recognized authority for medicinal mushrooms and their use. Famous medicinal mushroom Lentinus edodes (Shiitake). Used traditionally (and verified scientifically) for cancer, to lower cholesterol and blood sugar, and to boost the immune system against viruses. Myko San supplement Agarikon.1 kills cancer cells in culture. Left is the control, on the right a 50% concentration of a single component; the cytotoxic effect on squamous cell cancer is very strong.

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.